Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

95.98EUR
6:02pm IST
Change (% chg)

€-0.22 (-0.23%)
Prev Close
€96.20
Open
€95.74
Day's High
€96.22
Day's Low
€95.44
Volume
76,995
Avg. Vol
485,864
52-wk High
€102.90
52-wk Low
€85.06

Latest Key Developments (Source: Significant Developments)

Merck KGaA and Broad Institute Announce CRISPR License Framework to Encourage Innovation
Thursday, 18 Jul 2019 

July 18 (Reuters) - Merck KGaA ::MERCK KGAA - CO, BROAD INSTITUTE OF MIT & HARVARD ANNOUNCED AGREEMENT BETWEEN BROAD INSTITUTE & LIFE SCIENCE BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.MERCK KGAA - AGREEMENT TO OFFER NON-EXCLUSIVE LICENSES TO CRISPR INTELLECTUAL PROPERTY UNDER RESPECTIVE CONTROL FOR COMMERCIAL RESEARCH, PRODUCT DEVELOPMENT.  Full Article

Germany’s Merck Pleased With Intermolecular’s Shareholder Approval of Takeover
Thursday, 18 Jul 2019 

July 18 (Reuters) - Merck KGaA::VERY PLEASED WITH THIS POSITIVE DEVELOPMENT OF INTERMOLECULAR’S STOCKHOLDERS APPROVING OUR ACQUISITION PROPOSAL.TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.  Full Article

Merck KGaA Says FDA Approves Renal Cell Carcinoma Combination Therapy
Wednesday, 15 May 2019 

May 15 (Reuters) - Merck KGaA ::PHASE III STUDY SHOWED A 31% SIGNIFICANT REDUCTION IN THE RISK OF DISEASE PROGRESSION OR DEATH IN COMBINATION WITH SUNITINIB IN PATIENTS WITH ADVANCED RCC AND A PROGRESSION-FREE SURVIVAL (PFS) PROLONGED BY 5.4 MONTHS.COMBINATION APPROVED BASED ON PHASE III DATA IN AN OVERALL POPULATION THAT INCLUDED PATIENTS REGARDLESS OF PD-L1 EXPRESSION AND ACROSS FAVORABLE, INTERMEDIATE AND POOR PROGNOSTIC GROUPS.FDA GRANTS APPROVAL FOR COMBINATION OF BAVENCIO® (AVELUMAB) PLUS AXITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.  Full Article

Merck Says Signs Definitive Agreement To Buy Intermolecular
Monday, 6 May 2019 

May 6 (Reuters) - MERCK KGAA ::SIGNS DEFINITIVE AGREEMENT TO ACQUIRE INTERMOLECULAR FOR $1.20 PER SHARE IN AN ALL CASH TRANSACTION.TRANSACTION EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.ACQUISITION TO STRENGTHEN SEMICONDUCTOR TECHNOLOGY OFFERING.  Full Article

Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction
Monday, 6 May 2019 

May 6 (Reuters) - Intermolecular Inc ::INTERMOLECULAR TO BE ACQUIRED BY MERCK KGAA, DARMSTADT, GERMANY FOR $1.20 PER SHARE IN AN ALL CASH TRANSACTION.INTERMOLECULAR INC - DEAL FOR APPROXIMATELY $62 MILLION.INTERMOLECULAR INC - ACQUISITION HAS BEEN UNANIMOUSLY APPROVED BY INTERMOLECULAR'S BOARD OF DIRECTORS AND EXECUTIVE BOARD OF MERCK KGAA, DARMSTADT, GERMANY.INTERMOLECULAR INC - MERCK KGAA, DARMSTADT, GERMANY, WILL ACQUIRE INTERMOLECULAR THROUGH ITS WHOLLY OWNED SUBSIDIARY EMD GROUP HOLDING II, INC.  Full Article

Merck KGaA And European Space Agency Sign Letter Of Intent
Thursday, 2 May 2019 

May 2 (Reuters) - Merck KGaA ::MERCK AND THE EUROPEAN SPACE AGENCY (ESA) TODAY SIGNED A LETTER OF INTENT TO EXTEND BY A FURTHER TWO YEARS THEIR COOPERATION AGREEMENT FROM 2016..  Full Article

Merck KGaA: We Will Generate 2 Bln Euros A Year With New Drugs From 2022
Friday, 26 Apr 2019 

April 26 (Reuters) - Merck KGaA CEO Stefan Oschmann at company's annual general meeting ::CONFIRMS 2019 OUTLOOK OF MODERATE ORGANIC REVENUE GROWTH AND STRONG ORGANIC ADJUSTED EBITDA GROWTH - AGM SPEECH.THERE WILL BE ANNUAL REVENUES OF 2 BILLION EUR GENERATED BY NEW DRUGS FROM 2022.OUR LIFE SCIENCES BUSINESS SHOULD GROW FASTER THAN THE MARKET.CO TARGETS ANNUAL REVENUE GROWTH IN ELECTRONICS BUSINESS OF 2 TO 3 PERCENT, ADJUSTED EBITDA MARGIN OF AROUND 30 PERCENT.LOW POINT IN ELECTRONICS BUSINESS SHOULD BE REACHED THIS YEAR.  Full Article

Versum Materials Would Be Required To Pay Merck $235 Mln In Case Of Deal Termination
Friday, 12 Apr 2019 

April 12 (Reuters) - Merck KGaA ::VERSUM MATERIALS - WOULD BE REQUIRED TO PAY MERCK A TERMINATION FEE OF $235 MILLION IF CO ENTERS INTO AN AGREEMENT PROVIDING FOR A SUPERIOR PROPOSAL.VERSUM MATERIALS - IN CONNECTION WITH TERMINATION OF ENTEGRIS MERGER AGREEMENT, CO PAID TO ENTEGRIS A TERMINATION FEE OF $140 MILLION.VERSUM MATERIALS INC - IN CASE OF CHANGE OF RECOMMENDATION BY BOARD OF MERCK, CO TO PAY MERCK A TERMINATION FEE OF $235 MILLION.  Full Article

Merck Signs Definitive Agreement To Buy Versum Materials For $53 Per Share
Friday, 12 Apr 2019 

April 12 (Reuters) - MERCK KGAA ::SIGNS DEFINITIVE AGREEMENT TO ACQUIRE VERSUM MATERIALS FOR $53 PER SHARE.€75 MILLION IN EXPECTED RUN-RATE SYNERGIES BY THE THIRD FULL YEAR AFTER CLOSING.EXPECTED TO BE IMMEDIATELY ACCRETIVE TO EARNINGS PER SHARE PRE (EPS PRE).VERSUM HAS TERMINATED ITS PREVIOUSLY ANNOUNCED MERGER AGREEMENT WITH ENTEGRIS.AGREED UPON PRICE REFLECTS AN ENTERPRISE VALUE (EV) FOR VERSUM OF APPROXIMATELY €5.8 BILLION.TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.BUSINESS COMBINATION WILL BE FINANCED WITH CASH ON HAND AND DEBT BY WAY OF FACILITIES AGREEMENT WITH BANK OF AMERICA MERRILL LYNCH, BNP PARIBAS FORTIS AND DEUTSCHE BANK AG.  Full Article

Versum Materials Gets Revised Proposal From Merck KGaA
Monday, 8 Apr 2019 

April 8 (Reuters) - Versum Materials Inc ::VERSUM MATERIALS RECEIVES REVISED PROPOSAL FROM MERCK KGAA; BOARD DETERMINES REVISED OFFER CONSTITUTES A “SUPERIOR PROPOSAL” TO ENTEGRIS TRANSACTION.VERSUM MATERIALS INC - ENTEGRIS HAS RIGHT TO SUBMIT COUNTERPROPOSAL UNTIL APRIL 11.VERSUM MATERIALS INC - MERCK WOULD ACQUIRE ALL OF OUTSTANDING SHARES OF COMMON STOCK OF VERSUM FOR $53 PER SHARE IN CASH.VERSUM MATERIALS INC - MERCK PREVIOUSLY ANNOUNCED $48 PER SHARE PROPOSAL ON FEBRUARY 27, 2019.VERSUM MATERIALS - IF VERSUM TERMINATES ENTEGRIS DEAL TO ENTER AGREEMENT WITH RESPECT TO MERCK'S REVISED PROPOSAL, CO TO PAY $140 MILLION FEE TO ENTEGRIS.  Full Article